Literature DB >> 17504121

Non-homologous DNA end joining in anticancer therapy.

Elzbieta Pastwa1, Mariusz Malinowski.   

Abstract

Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become molecular targets in the treatment of cancer. Inhibition of this pathway leads to radio- and chemosensitization of cancer cells. This review will focus on the new therapeutic strategies for NHEJ pathway inhibition and their application in anticancer therapy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17504121     DOI： 10.2174/156800907780618284

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  3 in total

1.  The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

Authors:  Younghyun Lee; Huizi Keiko Li; Aya Masaoka; Shigeaki Sunada; Hirokazu Hirakawa; Akira Fujimori; Jac A Nickoloff; Ryuichi Okayasu
Journal:  Radiother Oncol       Date:  2016-09-22       Impact factor: 6.280

Review 2.  Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining.

Authors:  Brandi L Mahaney; Katheryn Meek; Susan P Lees-Miller
Journal:  Biochem J       Date:  2009-02-01       Impact factor: 3.857

Review 3.  In vitro non-homologous DNA end joining assays--the 20th anniversary.

Authors:  Elzbieta Pastwa; Richard I Somiari; Mariusz Malinowski; Stella B Somiari; Thomas A Winters
Journal:  Int J Biochem Cell Biol       Date:  2008-12-06       Impact factor: 5.652
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.